AU2762101A - N,o-amidomalonate platinum complexes - Google Patents

N,o-amidomalonate platinum complexes Download PDF

Info

Publication number
AU2762101A
AU2762101A AU27621/01A AU2762101A AU2762101A AU 2762101 A AU2762101 A AU 2762101A AU 27621/01 A AU27621/01 A AU 27621/01A AU 2762101 A AU2762101 A AU 2762101A AU 2762101 A AU2762101 A AU 2762101A
Authority
AU
Australia
Prior art keywords
platinum
polymer
chelate
composition
amidomalonate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU27621/01A
Other languages
English (en)
Inventor
John R. Rice
John V. St. John
Donald R. Stewart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abeona Therapeutics Inc
Original Assignee
Access Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Access Pharmaceuticals Inc filed Critical Access Pharmaceuticals Inc
Publication of AU2762101A publication Critical patent/AU2762101A/en
Priority to AU2006222657A priority Critical patent/AU2006222657B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0086—Platinum compounds
    • C07F15/0093—Platinum compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polyamides (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU27621/01A 2000-01-04 2001-01-04 N,o-amidomalonate platinum complexes Abandoned AU2762101A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2006222657A AU2006222657B2 (en) 2000-01-04 2006-09-22 N,O-amidomalonate platinum complexes

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17443500P 2000-01-04 2000-01-04
US60174435 2000-01-04
PCT/US2001/000284 WO2001049696A1 (en) 2000-01-04 2001-01-04 N,o-amidomalonate platinum complexes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2006222657A Division AU2006222657B2 (en) 2000-01-04 2006-09-22 N,O-amidomalonate platinum complexes

Publications (1)

Publication Number Publication Date
AU2762101A true AU2762101A (en) 2001-07-16

Family

ID=22636134

Family Applications (1)

Application Number Title Priority Date Filing Date
AU27621/01A Abandoned AU2762101A (en) 2000-01-04 2001-01-04 N,o-amidomalonate platinum complexes

Country Status (8)

Country Link
US (1) US6692734B2 (https=)
EP (1) EP1254145A1 (https=)
JP (2) JP5025062B2 (https=)
KR (1) KR100729015B1 (https=)
AU (1) AU2762101A (https=)
CA (1) CA2396702C (https=)
WO (1) WO2001049696A1 (https=)
ZA (1) ZA200205358B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7166733B2 (en) * 2000-01-04 2007-01-23 Access Pharmaceuticals, Inc. O,O'-Amidomalonate and N,O-Amidomalonate platinum complexes
US7138520B2 (en) * 2003-01-13 2006-11-21 Massachusetts Institute Of Technology Coordination complexes having tethered therapeutic agents and/or targeting moieties, and methods of making and using the same
WO2005002508A2 (en) * 2003-06-11 2005-01-13 Access Pharmaceuticals, Inc. Macromolecular platinum chelates
ATE465205T1 (de) 2005-12-05 2010-05-15 Nitto Denko Corp Polyglutamat-aminosäure-konjugate und verfahren
CN101730549B (zh) * 2007-05-09 2015-12-09 日东电工株式会社 与铂类药物结合的聚合物
CA2705850C (en) * 2007-11-13 2016-07-19 Bio-Technology General (Israel) Ltd. Dilute filtration sterilization process for viscoelastic biopolymers
BRPI0920655A2 (pt) * 2008-10-07 2019-07-09 Rexahn Pharmaceuticals, Inc. conjugados e hpma-docetaxel ou gencitabina e usos dos mesmos
JP5281358B2 (ja) * 2008-10-27 2013-09-04 学校法人常翔学園 高分子、経上皮吸収促進剤、及び医薬用製剤
KR101721865B1 (ko) * 2009-10-13 2017-04-03 렉산 파마슈티컬스, 인코포레이티드 항암제의 전달을 위한 폴리머 시스템
JP5684056B2 (ja) 2010-08-16 2015-03-11 株式会社マキタ 手持ち工具
US8946163B2 (en) 2012-11-19 2015-02-03 Mimedx Group, Inc. Cross-linked collagen comprising metallic anticancer agents
US10335433B2 (en) * 2013-04-10 2019-07-02 Mimedx Group, Inc. NDGA polymers and metal complexes thereof
WO2015035446A1 (en) * 2013-09-10 2015-03-19 Starpharma Pty Ltd Macromolecules of dendrimer-platinum conjugates
EP3315487B1 (en) 2015-06-24 2020-10-28 Nippon Kayaku Kabushiki Kaisha Novel platinum (iv) complex
AU2016324370B2 (en) 2015-09-14 2021-02-25 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of hexa-coordinated platinum complex
US20190231690A1 (en) * 2017-11-08 2019-08-01 L.E.A.F. Holdings Group Llc Platinum complexes and uses thereof
BR112021000658A2 (pt) 2018-07-19 2021-04-13 Starpharma Pty Ltd Dendrímero, composições, composição farmacêutica, método de tratamento de câncer, uso de dendrímero, método, uso, dendrímero ou composição, processo de produção de dendrímero e intermediários para a produção de dendrímero
US12071517B2 (en) 2018-07-19 2024-08-27 Starpharma Pty Ltd. Therapeutic dendrimer
CN113018311A (zh) * 2019-12-25 2021-06-25 沈阳药科大学 顺铂配合物以及顺铂配合物脂质体的制备方法
CN117105797B (zh) * 2023-08-25 2025-09-23 湖南科技大学 一种谷氨酸铂配合物及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO146404C (no) * 1979-10-26 1982-09-22 Dyno Industrier As Bygning for lyddempet skyting.
JPS5667326A (en) * 1979-11-05 1981-06-06 Hitachi Ltd Imide type compound and production thereof
IL67789A (en) 1983-01-31 1986-09-30 Yissum Res Dev Co Amino-substituted malonato platinum(ii)complexes and method for their preparation
EP0284197A1 (en) * 1987-02-20 1988-09-28 Tanabe Seiyaku Co., Ltd. Novel organic platinum complex and process for the preparation thereof
US4793986A (en) * 1987-02-25 1988-12-27 Johnson Matthey, Inc. Macromolecular platinum antitumor compounds
IL85595A0 (en) * 1987-03-06 1988-08-31 Tanabe Seiyaku Co Organic platinum complex and its preparation
JPS6494A (en) * 1987-03-06 1989-01-05 Tanabe Seiyaku Co Ltd Novel organoplatinum complex
JPH0256421A (ja) * 1988-08-19 1990-02-26 Tanabe Seiyaku Co Ltd 抗腫瘍剤
JPH0267217A (ja) * 1988-09-01 1990-03-07 Tanabe Seiyaku Co Ltd 抗腫瘍剤
US4946954A (en) * 1989-01-17 1990-08-07 Georgetown University Platinum pharmaceutical agents
KR0164460B1 (ko) 1995-10-02 1999-03-20 김은영 고분자 백금 착화합물, 그의 제조방법 및 그를 유효성분으로 하는 항암제
US5965118A (en) * 1997-04-18 1999-10-12 Access Pharmaceuticals, Inc. Polymer-platinum compounds

Also Published As

Publication number Publication date
US20010038830A1 (en) 2001-11-08
WO2001049696A1 (en) 2001-07-12
CA2396702C (en) 2010-03-23
KR20020082208A (ko) 2002-10-30
EP1254145A1 (en) 2002-11-06
US6692734B2 (en) 2004-02-17
JP5025062B2 (ja) 2012-09-12
CA2396702A1 (en) 2001-07-12
ZA200205358B (en) 2003-08-20
JP2011137046A (ja) 2011-07-14
JP2003530317A (ja) 2003-10-14
KR100729015B1 (ko) 2007-06-14

Similar Documents

Publication Publication Date Title
US6692734B2 (en) N,O-amidomalonate platinum complexes
US20070197427A1 (en) O,o'-amidomalonate and n,o-amidomalonate platinum complexes
Xiao et al. The use of polymeric platinum (IV) prodrugs to deliver multinuclear platinum (II) drugs with reduced systemic toxicity and enhanced antitumor efficacy
Haririan et al. Anionic linear-globular dendrimer-cis-platinum (II) conjugates promote cytotoxicity in vitro against different cancer cell lines
WO2018100561A1 (en) Coordination compounds, syntheses, nanoformulation and use thereof in oncology
Song et al. A cross-linked polymeric micellar delivery system for cisplatin (IV) complex
WO2005002508A2 (en) Macromolecular platinum chelates
US7005124B2 (en) Dendritic-antineoplastic drug delivery system
US20170100485A1 (en) Metal-polysaccharide conjugates: methods for cancer therapy
TW509573B (en) Polymer platinum compounds
WO2020052697A1 (en) Procedure for the preparation of selectively oxidized polysaccharides as anticancer-drug carriers
AU2006222657B2 (en) N,O-amidomalonate platinum complexes
Gou et al. Evaluation of interactions between platinum-/ruthenium-based anticancer agents and human serum albumin: development of HSA carrier for metal-based drugs
KR100807358B1 (ko) 암조직 선택성과 생분해성을 갖는 고리형 삼합체포스파젠-백금(ｉｉ) 착물 컨쥬게이트 항암제 및 그 제조방법
AU2012202161A1 (en) O,O'-amidomalonate and N,O-amidomalonate platinum complexes
WO2018100562A1 (en) Coordination compounds, syntheses, nanoformulation and use thereof in oncology
Ferguson Exploring Polymer and Liposomal Carriers for Optimized Drug Delivery
Manocha et al. Research Article Controlled Release of Doxorubicin from Doxorubicin/γ-Polyglutamic Acid Ionic Complex
PL227543B1 (pl) Sposób wytwarzania koniugatu fibrynogenu glikowanego glukozą z metotreksatem